Sumitomo Pharma Co.ltd. · TSE:4506

Sumitomo Pharma Co.ltd — Dainippon Sumitomo Pharma — Technical Presentation (November 2005)

22 slides from Sumitomo Pharma Co.ltd's technical presentation, Nov 9, 2005

  1. Slide 1: Dainippon Sumitomo Pharma

    DAINIPPON sh SUMITOMO JY PHARMA

  2. Slide 2: SM-13496, SM-26000

    SM-13496 SM-26000) PHARMA

  3. Slide 3: f, DAINIPPON

    f, DAINIPPON & Py SUMITOMO 4 PHarma

  4. Slide 4: <fa DAINIPPON

    <fa DAINIPPON —! J Y Sad rig 7) a> >

  5. Slide 5: f: DAINIPPON

    f: DAINIPPON & Py SUMITOMO 4 PHARMA

  6. Slide 6: SM-13496

    f, DAINIPPON é Py SUMITOMO J Y PHARMA SM-13496

  7. Slide 7: SM-13496

    fA DAINIPPON = <> sumitomo 4 PHARMA SM-13496

  8. Slide 8: SM-13496 (Lurasidone) chemical structure and related compounds

    (SM-13496) H H O N N N N S HCl H O H H H H O Lurasidone, D2/5-HT7, 5-HT1A, 5-HT2 N N (CH2)4 N N S HCl 2H2O H O Lullan®, D2/5-HT2 antagonist H O N CH2COOH N (CH2)4 N N HO C COOH N CH2COOH H O Sediel®, 5-HT1A agonist (Anti-anxiety) 7

  9. Slide 9: SM-13496 Phase II

    SM-13496 <fa Ts = DAINIPPON SUMITOMO ARMA

  10. Slide 10: SM-13496 trial design

    II - - - 6 - SM-13496 40mg, SM-13496 120mg - SM-13496 80mg - BPRS, PANSS 9

  11. Slide 11: PANSS change results

    PANSS - SM-13496 40 mg 80 mg 120 mg (n=45) (n=90) (n=47) (n=90) (n=44) 0.0 -5.0 -10.0 -15.0 * -20.0 * * : p<0.05 II II 10

  12. Slide 12: PANSS subscale results

    PANSS - SM-13496 40 mg 80 mg 120 mg (n=45) (n=90) (n=47) (n=90) (n=44) 0.0 -0.5 -1.0 -1.5 -2.0 -2.5 -3.0 -3.5 * -4.0 * * : p<0.05 II II 11

  13. Slide 13: PANSS subscale results

    PANSS - SM-13496 40 mg 80 mg 120 mg (n=45) (n=90) (n=47) (n=89) (n=44) 0 -1 -2 * -3 * : p<0.05 II II 12

  14. Slide 14: SM-13496 80mg results

    SM-13496 80mg (n=83) (n=86) 0 -1 -2 -3 * -4 * : p<0.05 II 13

  15. Slide 15: SAS, BAS, AIMS safety scales

    3 SM-13496 2 SAS BAS AIMS 1 * 0 n=139 n=187 n=138 n=187 n=138 n=186 -1 SAS: Simpson-Angus Rating Scale * : p<0.05 BAS: Barnes Akathisia Scale AIMS: Abnormal Involuntary Movement Scale II II 14

  16. Slide 16: SM-13496

    SM-13496 - fA DAINIPPON = <> sumitomo J Y PHARMA 15

  17. Slide 17: SM-26000

    f, DAINIPPON é Py SUMITOMO J Y PHARMA SM-26000) 16

  18. Slide 18: SM-26000 with Gilead Sciences

    (SM-26000) 50mg Gilead Sciences B 17

  19. Slide 19: @ @ @ @ | @ @ Nn > @ @ @ @ @

    @ @ @ @ | @ @ Nn > @ @ @ @ @

  20. Slide 20: 3mg/kg vs 0.6mg/kg dose results

    3mg/kg 0.6mg/kg n=343) (n=344) 171 ( 49.9%) 169 ((49.1%) / 35 (10.2%) 147 (42.7%) 24 ( 7.0%) 70 (20.3%) > 1.5 101 (29.4%) 170 (49.4%) # ( ) >2.0 64 (18.7%) 116 (33.7%) # K <2.5 mM 23 ( 6.7%) 40 (11.6%) # p<0.05 p<0.001 19

  21. Slide 21: SM-26000

    SM-26000 - fa DAINIPPON é ~~ SUMITOMO J PHARMA 20

  22. Slide 22: Slide 22

Dainippon Sumitomo Pharma — Technical Presentation (November 2005) on 6ix